Cargando…
Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium
BACKGROUND: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820956/ https://www.ncbi.nlm.nih.gov/pubmed/27044418 http://dx.doi.org/10.1186/s12916-016-0607-5 |
_version_ | 1782425505506525184 |
---|---|
author | Ordóñez-Mena, José Manuel Schöttker, Ben Mons, Ute Jenab, Mazda Freisling, Heinz Bueno-de-Mesquita, Bas O’Doherty, Mark G. Scott, Angela Kee, Frank Stricker, Bruno H. Hofman, Albert de Keyser, Catherine E. Ruiter, Rikje Söderberg, Stefan Jousilahti, Pekka Kuulasmaa, Kari Freedman, Neal D. Wilsgaard, Tom de Groot, Lisette CPGM Kampman, Ellen Håkansson, Niclas Orsini, Nicola Wolk, Alicja Nilsson, Lena Maria Tjønneland, Anne Pająk, Andrzej Malyutina, Sofia Kubínová, Růžena Tamosiunas, Abdonas Bobak, Martin Katsoulis, Michail Orfanos, Philippos Boffetta, Paolo Trichopoulou, Antonia Brenner, Hermann |
author_facet | Ordóñez-Mena, José Manuel Schöttker, Ben Mons, Ute Jenab, Mazda Freisling, Heinz Bueno-de-Mesquita, Bas O’Doherty, Mark G. Scott, Angela Kee, Frank Stricker, Bruno H. Hofman, Albert de Keyser, Catherine E. Ruiter, Rikje Söderberg, Stefan Jousilahti, Pekka Kuulasmaa, Kari Freedman, Neal D. Wilsgaard, Tom de Groot, Lisette CPGM Kampman, Ellen Håkansson, Niclas Orsini, Nicola Wolk, Alicja Nilsson, Lena Maria Tjønneland, Anne Pająk, Andrzej Malyutina, Sofia Kubínová, Růžena Tamosiunas, Abdonas Bobak, Martin Katsoulis, Michail Orfanos, Philippos Boffetta, Paolo Trichopoulou, Antonia Brenner, Hermann |
author_sort | Ordóñez-Mena, José Manuel |
collection | PubMed |
description | BACKGROUND: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. METHODS: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. RESULTS: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. CONCLUSIONS: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0607-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4820956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48209562016-04-06 Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium Ordóñez-Mena, José Manuel Schöttker, Ben Mons, Ute Jenab, Mazda Freisling, Heinz Bueno-de-Mesquita, Bas O’Doherty, Mark G. Scott, Angela Kee, Frank Stricker, Bruno H. Hofman, Albert de Keyser, Catherine E. Ruiter, Rikje Söderberg, Stefan Jousilahti, Pekka Kuulasmaa, Kari Freedman, Neal D. Wilsgaard, Tom de Groot, Lisette CPGM Kampman, Ellen Håkansson, Niclas Orsini, Nicola Wolk, Alicja Nilsson, Lena Maria Tjønneland, Anne Pająk, Andrzej Malyutina, Sofia Kubínová, Růžena Tamosiunas, Abdonas Bobak, Martin Katsoulis, Michail Orfanos, Philippos Boffetta, Paolo Trichopoulou, Antonia Brenner, Hermann BMC Med Research Article BACKGROUND: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. METHODS: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. RESULTS: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. CONCLUSIONS: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0607-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-05 /pmc/articles/PMC4820956/ /pubmed/27044418 http://dx.doi.org/10.1186/s12916-016-0607-5 Text en © Ordóñez-Mena et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ordóñez-Mena, José Manuel Schöttker, Ben Mons, Ute Jenab, Mazda Freisling, Heinz Bueno-de-Mesquita, Bas O’Doherty, Mark G. Scott, Angela Kee, Frank Stricker, Bruno H. Hofman, Albert de Keyser, Catherine E. Ruiter, Rikje Söderberg, Stefan Jousilahti, Pekka Kuulasmaa, Kari Freedman, Neal D. Wilsgaard, Tom de Groot, Lisette CPGM Kampman, Ellen Håkansson, Niclas Orsini, Nicola Wolk, Alicja Nilsson, Lena Maria Tjønneland, Anne Pająk, Andrzej Malyutina, Sofia Kubínová, Růžena Tamosiunas, Abdonas Bobak, Martin Katsoulis, Michail Orfanos, Philippos Boffetta, Paolo Trichopoulou, Antonia Brenner, Hermann Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title_full | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title_fullStr | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title_full_unstemmed | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title_short | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
title_sort | quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the chances consortium |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820956/ https://www.ncbi.nlm.nih.gov/pubmed/27044418 http://dx.doi.org/10.1186/s12916-016-0607-5 |
work_keys_str_mv | AT ordonezmenajosemanuel quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT schottkerben quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT monsute quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT jenabmazda quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT freislingheinz quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT buenodemesquitabas quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT odohertymarkg quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT scottangela quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT keefrank quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT strickerbrunoh quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT hofmanalbert quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT dekeysercatherinee quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT ruiterrikje quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT soderbergstefan quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT jousilahtipekka quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kuulasmaakari quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT freedmanneald quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT wilsgaardtom quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT degrootlisettecpgm quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kampmanellen quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT hakanssonniclas quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT orsininicola quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT wolkalicja quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT nilssonlenamaria quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT tjønnelandanne quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT pajakandrzej quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT malyutinasofia quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT kubinovaruzena quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT tamosiunasabdonas quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT bobakmartin quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT katsoulismichail quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT orfanosphilippos quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT boffettapaolo quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT trichopoulouantonia quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT brennerhermann quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium AT quantificationofthesmokingassociatedcancerriskwithrateadvancementperiodsmetaanalysisofindividualparticipantdatafromcohortsofthechancesconsortium |